ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Raised by FAS Wealth Partners Inc.

FAS Wealth Partners Inc. raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 47.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 139,535 shares of the company's stock after buying an additional 44,830 shares during the quarter. FAS Wealth Partners Inc. owned about 0.14% of ARS Pharmaceuticals worth $1,755,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of ARS Pharmaceuticals by 7.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 368,556 shares of the company's stock worth $4,636,000 after purchasing an additional 24,385 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of ARS Pharmaceuticals by 47.1% during the fourth quarter. Wells Fargo & Company MN now owns 41,701 shares of the company's stock worth $440,000 after purchasing an additional 13,361 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of ARS Pharmaceuticals during the first quarter worth $189,000. Vanguard Group Inc. boosted its holdings in shares of ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock worth $36,555,000 after purchasing an additional 115,656 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of ARS Pharmaceuticals by 4.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company's stock worth $636,000 after purchasing an additional 2,670 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 28th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Trading Down 2.3%

Shares of SPRY traded down $0.43 during trading hours on Friday, hitting $17.92. The stock had a trading volume of 1,336,152 shares, compared to its average volume of 1,362,538. The company's fifty day simple moving average is $15.61 and its 200 day simple moving average is $13.66. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. ARS Pharmaceuticals, Inc. has a 12-month low of $8.91 and a 12-month high of $18.90. The firm has a market cap of $1.76 billion, a P/E ratio of -111.99 and a beta of 0.90.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.35). ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. The business had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. Equities research analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 740,149 shares of ARS Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares in the company, valued at $90,218,708.84. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kathleen D. Scott sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $705,000.00. Following the completion of the transaction, the chief financial officer owned 7,424 shares of the company's stock, valued at approximately $104,678.40. The trade was a 87.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,043,118 shares of company stock valued at $18,024,863. 33.50% of the stock is owned by company insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.